Literature DB >> 26187015

Design, synthesis and cytotoxicity studies of dithiocarbamate ester derivatives of emetine in prostate cancer cell lines.

Emmanuel S Akinboye1, Zebalda D Bamji2, Bernard Kwabi-Addo2, David Ejeh3, Robert L Copeland4, Samuel R Denmeade5, Oladapo Bakare6.   

Abstract

A small library of emetine dithiocarbamate ester derivatives were synthesized in 25-86% yield via derivatization of the N2'- position of emetine. Anticancer evaluation of these compounds in androgen receptor positive LNCaP and androgen receptor negative PC3 and DU145 prostate cancer cell lines revealed time dependent and dose-dependent cytotoxicity. With the exception of compound 4c, all the dithiocarbamate ester analogs in this study showed appreciable potency in all the prostate cancer cell lines (regardless of whether it is androgen receptor positive or negative) with a cytotoxicity IC50 value ranging from 1.312 ± 0.032 μM to 5.201 ± 0.125 μM by day 7 of treatment. Compared to the sodium dithiocarbamate salt 1, all the dithiocarbamate ester analogs (2 and 4a-4 g) displayed lower cytotoxicity than compound 1 (PC3, IC50 = 0.087 ± 0.005 μM; DU145, IC50 = 0.079 ± 0.003 μM and LNCaP, IC50 = 0.079 ± 0.003 μM) on day 7 of treatment. Consequently, it appears that S-alkylation of compound 1 leads to a more stable dithiocarbamate ester derivative that resulted in lower anticancer activity in the prostate cancer cell lines.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Anti-cancer activities; Dithiocarbamate ester; Emetine; Emetine derivatives; Prostate cancer

Mesh:

Substances:

Year:  2015        PMID: 26187015      PMCID: PMC6481605          DOI: 10.1016/j.bmc.2015.06.072

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  20 in total

1.  The alkaloid emetine as a promising agent for the induction and enhancement of drug-induced apoptosis in leukemia cells.

Authors:  Maren Möller; Kerstin Herzer; Till Wenger; Ingrid Herr; Michael Wink
Journal:  Oncol Rep       Date:  2007-09       Impact factor: 3.906

2.  Bivalent probes of the human multidrug transporter P-glycoprotein.

Authors:  Marcos M Pires; Christine A Hrycyna; Jean Chmielewski
Journal:  Biochemistry       Date:  2006-09-26       Impact factor: 3.162

3.  Phase I-II evaluation of emetine (NSC-33669) in the treatment of epidermoid bronchogenic carcinoma.

Authors:  R C Kane; M H Cohen; L E Broder; M I Bull; P J Creaven; B E Fossieck
Journal:  Cancer Chemother Rep       Date:  1975 Nov-Dec

4.  Structure-activity relationships of antineoplastic agents in multidrug resistance.

Authors:  C D Selassie; C Hansch; T A Khwaja
Journal:  J Med Chem       Date:  1990-07       Impact factor: 7.446

5.  Synthesis and in vitro antitumor activity of 4(3H)-quinazolinone derivatives with dithiocarbamate side chains.

Authors:  Sheng-Li Cao; Yu-Ping Feng; Yu-Yang Jiang; Shi-Ying Liu; Guo-Yu Ding; Run-Tao Li
Journal:  Bioorg Med Chem Lett       Date:  2005-04-01       Impact factor: 2.823

6.  Terpenoid tetrahydroisoquinoline alkaloids emetine, klugine, and isocephaeline inhibit the activation of hypoxia-inducible factor-1 in breast tumor cells.

Authors:  Yu-Dong Zhou; Yong-Pil Kim; Kaleem Asjad Mohammed; Deborah K Jones; Ilias Muhammad; D Chuck Dunbar; Dale G Nagle
Journal:  J Nat Prod       Date:  2005-06       Impact factor: 4.050

7.  Rational use of in vitro P-glycoprotein assays in drug discovery.

Authors:  J W Polli; S A Wring; J E Humphreys; L Huang; J B Morgan; L O Webster; C S Serabjit-Singh
Journal:  J Pharmacol Exp Ther       Date:  2001-11       Impact factor: 4.030

8.  Emetine regulates the alternative splicing of Bcl-x through a protein phosphatase 1-dependent mechanism.

Authors:  Kritsanapol Boon-Unge; Qingming Yu; Tie Zou; An Zhou; Piyarat Govitrapong; Jianhua Zhou
Journal:  Chem Biol       Date:  2007-12

9.  Design, synthesis, and evaluation of pH-dependent hydrolyzable emetine analogues as treatment for prostate cancer.

Authors:  Emmanuel S Akinboye; Marc D Rosen; Samuel R Denmeade; Bernard Kwabi-Addo; Oladapo Bakare
Journal:  J Med Chem       Date:  2012-08-16       Impact factor: 7.446

10.  Using small molecules to overcome drug resistance induced by a viral oncogene.

Authors:  Inese Smukste; Oneil Bhalala; Marco Persico; Brent R Stockwell
Journal:  Cancer Cell       Date:  2006-02       Impact factor: 31.743

View more
  5 in total

Review 1.  Different Aspects of Emetine's Capabilities as a Highly Potent SARS-CoV-2 Inhibitor against COVID-19.

Authors:  Mehdi Valipour
Journal:  ACS Pharmacol Transl Sci       Date:  2022-05-23

2.  Anticancer activities of emetine prodrugs that are proteolytically activated by the prostate specific antigen (PSA) and evaluation of in vivo toxicity of emetine derivatives.

Authors:  Emmanuel S Akinboye; Marc D Rosen; Oladapo Bakare; Samuel R Denmeade
Journal:  Bioorg Med Chem       Date:  2017-11-10       Impact factor: 3.641

3.  Emetine exhibits anticancer activity in breast cancer cells as an antagonist of Wnt/β‑catenin signaling.

Authors:  Qi Sun; Qiuxia Fu; Shiyue Li; Junjun Li; Shanshan Liu; Zhongyuan Wang; Zijie Su; Jiaxing Song; Desheng Lu
Journal:  Oncol Rep       Date:  2019-08-22       Impact factor: 3.906

4.  Sulfonamide-Derived Dithiocarbamate Gold(I) Complexes Induce the Apoptosis of Colon Cancer Cells by the Activation of Caspase 3 and Redox Imbalance.

Authors:  Javier Quero; José Carlos Royo; Beatrice Fodor; María Concepción Gimeno; Jesús Osada; María Jesús Rodríguez-Yoldi; Elena Cerrada
Journal:  Biomedicines       Date:  2022-06-17

5.  Multicomponent synthesis of some new (1S,4S)-2,5-diazabicyclo[2.2.1]heptane-dithiocarbamates and their in vitro anti-proliferative activity against CaSki, MDA-MB-231 and SK-Lu-1 tumour cells as apoptosis inducing agents without necrosis.

Authors:  Sujay Laskar; Luis Sánchez-Sánchez; Manuel López-Ortiz; Hugo López-Muñoz; María L Escobar-Sánchez; Arturo T Sánchez; Ignacio Regla
Journal:  J Enzyme Inhib Med Chem       Date:  2017-12       Impact factor: 5.051

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.